Hepalink Pharma kicks off $585m Hong Kong listing
Shenzhen Hepalink Pharmaceutical Group launched its Hong Kong IPO this week, targeting proceeds of HK$4.53bn ($585m).
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: